[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"single-embryo-transfer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:single-embryo-transfer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100529733","advantages-of-early-intrauterine-transfer-of-blank-culture-medium-prior-to-1st-or-2nd-transfer-of-thawed-embryos-100529733",false,"NCT06177613","Advantages of Early Intrauterine Transfer of \"Blank\" Culture Medium Prior to 1st or 2nd Transfer of Thawed Embryo(s).","Advantages of Early Intrauterine Transfer of \"Blank\" Culture Medium Prior to 1st or 2nd Transfer of Thawed Embryo(s). Randomized, Single-blind, Multicenter Controlled Trial.","TRABLAN","Inclusion Criteria:\n\n* Having had a first \"fresh\" or frozen embryo transfer, whatever the embryo's stage of development, transfer followed by pregnancy failure ;\n* Frozen embryos must be at least D3 stage;\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study\n* The patient is under safeguard of justice or state guardianship","FEMALE",{"count":19,"type":20},1154,"ESTIMATED","INTERVENTIONAL",[23],"NA","Despite technical advances in Medically Assisted Reproduction (AMP), the success of fertility treatments is sometimes limited by embryo implantation failure. The coordinated development of the embryo and the uterine endometrium requires close communication between the maternal tissue and the embryo. In in vitro fertilization (IVF), embryo transfer generally takes place between the 2nd (D2) and the 6th (D6) day following oocyte fertilization. Recent studies have shown the advantages of sequential transfer (transfer of an embryo on D2\u002FD3 followed by the transfer of another embryo on D5\u002FD6), with higher implantation and clinical pregnancy rate, fewer miscarriages, more live births, and yet no increase in multiple pregnancies. However, the American Society for Reproductive Medicine recommendations continue to prioritize the transfer of a single embryo for all patients aged under 38. To improve pregnancy rates for patients having a single embryo transferred, the study investigators wish to carry out on \"blank\" transfer, based on the principle of sequential transfer. The study investigators hypothesize that a culture medium, placed in the uterus before the time of embryo transfer, will modify immune tolerance. The study will test whether transferring the same culture medium in an equivalent quantity as during the real transfer into the uterus 2\u002F3 days before the embryo transfer will improve tolerance to this foreign medium and, therefore, embryo implantation. The aim of this study is thus to evaluate the impact of a \"blank\" transfer with culture medium alone, on the results of frozen embryo transfers (FET) from IVF.",[26,27],"Single Embryo Transfer","Fertilization in Vitro","RECRUITING","2025-02-19",{"date":31,"type":32},"2025-02-20","ACTUAL",{"date":34,"type":32},"2024-02-09",{"date":36,"type":20},"2027-02",{"name":38,"class":39},"Centre Hospitalier Universitaire de Nīmes","OTHER",7,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":5},"100554812","impact-of-uterine-immune-profiling-and-personalized-treatments-in-patients-receiving-a-single-blastocyst-a-matched-controlled-study-100554812","NCT06503952","Impact of Uterine Immune Profiling and Personalized Treatments in Patients Receiving a Single Blastocyst: a Matched Controlled Study","Impact of Uterine Immune Profiling and Personalized Treatments on Subsequent Live Birth in Patients Receiving a Single Blastocyst: a Matched Controlled Study","UTIMPROSET","For case: Uterine immune profiling followed by a Day-5 fresh SET or day-5 or Day-6 freeze-thawed SET within the nine months following the uterine immune profiling between January 2020 and June 2023.\n\nWill be excluded patients with no SET day-5, with uterine immune profiling more than nine months before, or with no matching pair For control: Blastocyst SET without uterine immune profiling within the year prior the embryo transfer matched to the case group between January 2018 on June 2023\n\n* maternal age (+\u002F-1 year) and\n* the past history of ART (same number of previous oocytes pick-up, same number of previous embryo transfer) and\n* the same type of transfer (IVF, ICSI, frozen transfer) and\n* the same category of expansion of the blastocoel (B1-B2\u002F B3-B4\u002F B5-B6).","18 Years","41 Years",{"count":52,"type":20},340,"OBSERVATIONAL","A recent randomised controlled trial and previous large cohort studies have shown that the uterine immune environment is a crucial element in improving the performance of Assisted Reproductive therapy (ART). As previous studies mixed Day-3, Day-5, single or doble embryo transfer, the clear influence of the endometrial environment on the embryo itself and its type of transfer (fresh or freeze thawed) need further investigation.\n\nTo complement previous studies, the present matched- pair study aims to select the population who exclusively received a single Day-5 embryo transfer (SET) and benefitted of a uterine immune profiling between 1 January 2020 and 30 June 2023 before the SET Day-5.\n\nThis population will be matched to a population. who did not have uterine immune profiling in the nine months prior to the single Day 5 embryo transfer between 2018 and 2023.\n\nThe matching criteria are the maternal age (+\u002F-1 year), the past history of ART (same number of previous oocytes pick-up, same number of previous embryo transfer) and the same type of transfer (IVF, ICSI, frozen transfer) and the same category of expansion of the blastocoel (B1-B2\u002F B3-B4\u002F B5-B6).\n\nThe primary end-point is the live birth rate (LBR) following the Day 5 SET in the population who benefited from pre-SET immune profiling versus the LBR following the Day 5 SET in the pair- matched population who did not benefit from pre-SET uterine immune profiling Secondary end point are the clinical pregnancy rate and miscarriage rate per SET in the two paired populations",[56,57,26,58,59,60],"Infertility","Success Rate of Assisted Reproductive Therapy","Pregnancy Outcomes","Immunological Tolerance","Immune System",[62,63,64,65,66,67],"infertility","success rate of assisted reproductibve therapy","Single embryo transfer","uterine immune profiling","personalized care","Live birth rate","NOT_YET_RECRUITING","2024-12-20",{"date":71,"type":32},"2024-12-27",{"date":73,"type":20},"2025-01-15",{"date":75,"type":20},"2025-05-30",{"name":77,"class":39},"Matricelab Innove"]